000166486 001__ 166486
000166486 005__ 20240229123230.0
000166486 0247_ $$2doi$$a10.3389/fonc.2020.586449
000166486 0247_ $$2pmid$$apmid:33335856
000166486 0247_ $$2pmc$$apmc:PMC7736629
000166486 037__ $$aDKFZ-2020-02929
000166486 041__ $$aeng
000166486 082__ $$a610
000166486 1001_ $$aEichkorn, Tanja$$b0
000166486 245__ $$aConsolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration Rates.
000166486 260__ $$aLausanne$$bFrontiers Media$$c2020
000166486 3367_ $$2DRIVER$$aarticle
000166486 3367_ $$2DataCite$$aOutput Types/Journal article
000166486 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1609147402_24571
000166486 3367_ $$2BibTeX$$aARTICLE
000166486 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166486 3367_ $$00$$2EndNote$$aJournal Article
000166486 520__ $$aThe PACIFC trial demonstrated a significant benefit of durvalumab consolidation immunotherapy (CIT) after definitive platinum-based chemoradiotherapy (P-CRT) for survival in stage III non-small cell lung cancer (NSCLC). It is unknown how many patients are eligible in clinical practice to receive CIT according to PACIFIC criteria compared to real administration rates and what influencing factors are.We analyzed 442 patients with unresectable stage III NSCLC who received P-CRT between 2009 and 2019 regarding CIT eligibility rates according to PACIFIC criteria and administration rates since drug approval.Sixty-four percent of 437 patients were male, median age was 63 years [interquartile range (IQR): 57-69]. The most common histologic subtypes were adenocarcinoma (42.8%) and squamous cell carcinoma (41.1%), most tumors were in stage IIIB (56.8%). Mean PD-L1 tumor proportion score (TPS) was 29.8% (IQR: 1-60). The median total RT dose was 60 Gy (IQR: 60-66). Platinum component of P-CRT was evenly distributed between cisplatin (51.4%) and carboplatin (48.6%). 50.3% of patients were eligible for CIT according to PACIFIC criteria. Observed contraindications were progressive disease according to RECIST (32.4%), followed by a PD-L1 TPS < 1% (22.3%), pneumonitis CTCAE ≥ 2 (12.6%) and others (4.9%). One year after drug approval, 85.6% of patients who were eligible according to PACIFIC criteria actually received CIT. Time interval between chemotherapy start and radiation therapy start (OR 0.9, 95% CI: [0.9; 1.0] p = 0.009) and probably cisplatin as platinum-component of P-CRT (OR 1.5, 95% CI: [1.0; 2.4] p < 0.061) influence CIT eligibility. Highly positive PD-L1 TPS (≥50%; (OR 2.4, 95% CI: [1.3; 4.5] p = 0.004) was associated to a better chance for CIT eligibility.Eighty-five percent of potentially eligible patients received CIT one year after drug approval. Fifty percent of patients did not meet PACIFIC criteria for durvalumab eligibility, this was mainly caused by disease progression during platinum-based CRT, followed by therapy-related pneumonitis and PD-L1 TPS < 1% (in view of the EMA drug approval).
000166486 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000166486 588__ $$aDataset connected to CrossRef, PubMed,
000166486 650_7 $$2Other$$aPACIFIC criteria
000166486 650_7 $$2Other$$adefinitive platinum-based chemoradiotherapy
000166486 650_7 $$2Other$$adurvalumab admission rate
000166486 650_7 $$2Other$$adurvalumab eligibility rate
000166486 650_7 $$2Other$$anon-small cell lung cancer stage III
000166486 7001_ $$aBozorgmehr, Farastuk$$b1
000166486 7001_ $$aRegnery, Sebastian$$b2
000166486 7001_ $$aDinges, Lisa A$$b3
000166486 7001_ $$0P:(DE-He78)a3cba63a64575c64aa367077f673531d$$aKudak, Andreas$$b4$$udkfz
000166486 7001_ $$0P:(DE-He78)5d82cce0b2bdf38ce566c6de847a5537$$aBougatf, Nina$$b5$$udkfz
000166486 7001_ $$aWeber, Dorothea$$b6
000166486 7001_ $$aChristopoulos, Petros$$b7
000166486 7001_ $$aMuley, Thomas$$b8
000166486 7001_ $$aKobinger, Sonja$$b9
000166486 7001_ $$aKönig, Laila$$b10
000166486 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b11$$udkfz
000166486 7001_ $$aAdeberg, Sebastian$$b12
000166486 7001_ $$aHeussel, Claus Peter$$b13
000166486 7001_ $$aThomas, Michael$$b14
000166486 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b15$$udkfz
000166486 7001_ $$aEl Shafie, Rami A$$b16
000166486 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2020.586449$$gVol. 10, p. 586449$$p586449$$tFrontiers in oncology$$v10$$x2234-943X$$y2020
000166486 909CO $$ooai:inrepo02.dkfz.de:166486$$pVDB
000166486 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a3cba63a64575c64aa367077f673531d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000166486 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5d82cce0b2bdf38ce566c6de847a5537$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000166486 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000166486 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000166486 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000166486 9141_ $$y2020
000166486 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2018$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-06
000166486 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-06
000166486 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-06
000166486 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000166486 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000166486 980__ $$ajournal
000166486 980__ $$aVDB
000166486 980__ $$aI:(DE-He78)E050-20160331
000166486 980__ $$aI:(DE-He78)HD01-20160331
000166486 980__ $$aUNRESTRICTED